Chelstrom L M, Finnegan D, Uckun F M
Department of Therapeutic Radiology-Radiation Oncology, University of Minnesota Health Sciences Center, Minneapolis 55455.
Leuk Lymphoma. 1992 May;7(1-2):79-86. doi: 10.3109/10428199209053605.
Murine BCL-1 B-cell leukemia provides a model of disseminated human B-lineage acute lymphoblastic leukemia (ALL) and non-Hodgkins lymphoma (NHL). This model was used to evaluate and compare the anti-leukemic efficacy of recombinant cytokines rIL-1 beta, rIL-2, rIL-6, rTNF alpha, rG-CSF, rGM-CSF and their combinations. Of these 6 cytokines tested, rG-CSF, rIL-1 beta, rIL-2, and rTNF alpha exerted a marked anti-leukemia/lymphoma activity, as reflected by significantly improved survival of treated mice after inoculation of BCL-1 cells. Notably, no additive or synergistic effects were observed when 2-4 cytokines were used in combination. To our knowledge, this report represents the first comparative analysis of recombinant cytokine treatment regimens in an animal model of disseminated B-lineage ALL/NHL.
小鼠BCL-1 B细胞白血病为播散性人类B系急性淋巴细胞白血病（ALL）和非霍奇金淋巴瘤（NHL）提供了一个模型。该模型用于评估和比较重组细胞因子rIL-1β、rIL-2、rIL-6、rTNFα、rG-CSF、rGM-CSF及其组合的抗白血病疗效。在所测试的这6种细胞因子中，rG-CSF、rIL-1β、rIL-2和rTNFα表现出显著的抗白血病/淋巴瘤活性，接种BCL-1细胞后，治疗小鼠的存活率显著提高即反映了这一点。值得注意的是，当联合使用2 - 4种细胞因子时，未观察到相加或协同效应。据我们所知，本报告是在播散性B系ALL/NHL动物模型中对重组细胞因子治疗方案进行的首次比较分析。
